SAB BIOTHERAPEUTICS, INC.
(SABS)Financial Statements · SEC EDGAR XBRL
Revenue
$0
-100.0%
Net Income
$13.3M
+138.9%
EPS
$-0.79
+78.5%
Op. Income
-$49.0M
-14.1%
FCF
-$45.7M
-32.0%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)